Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis

Pharmacogenetics and Genomics

Volumn 24, Issue 8, 2014, Pages 401-405

  Enevold, Christian ^a   Baslund, Bo ^a   Linde, Louise ^b   Josephsen, Norah L ^c   Tarp, Ulrik ^c   Lindegaard, Hanne ^d   Jacobsen, Søren ^a   Nielsen, Claus H ^b  

^a Rigshospitalet   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

interleukin 6; interleukin 6 receptor; personalized medicine; rheumatoid arthritis; single nucleotide polymorphism; tocilizumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB;

ADULT; AGED; ALLELE; ARTICLE; DAS28; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-6; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84904256239     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000071     Document Type: Article

References (10)

1. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69:88-96.
2. Hamid YH, Urhammer SA, Jensen DP, Glümer C, Borch-Johnsen K, Jørgensen T, et al. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 2004; 53:3342-3345.
3. Qi L, Rifai N, Hu FB. Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in women. Diabetes 2009; 58:275-278.
4. Revez Ja, Bain L, Chapman B, Powell JE, Jansen R, Duffy DL, et al. A new regulatory variant in the interleukin-6 receptor gene associates with asthma risk. Genes Immun 2013; 14:441-446.
5. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Cri. Arthritis Rheum 1996; 39:34-40.
6. Enevold C, Oturai AB, Sørensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J Neuroimmunol 2009; 212 (1-2):125-131.
7. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112:3959-3964.
8. Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2013; 13:235-241.
9. Lamas JR, Rodriguez-Rodriguez L, Varade J, López-Romero P, Tornero-Esteban P, Abasolo L, et al. Influence of IL6R rs8192284 polymorphism status in disease activity in rheumatoid arthritis. J Rheumatol 2010; 37:1579-1581.
10. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 2011; 21:370-374.